Navigation Links
Singulex Closes $19 Million Financing Round
Date:1/12/2009

ALAMEDA, Calif., Jan. 12 /PRNewswire/ -- Singulex, Inc. today announced that it has closed a $19 million financing round, led by JAFCO Co., Ltd. and supported by existing investors including OrbiMed Advisors and Fisk Ventures. The financing round will support the commercialization of Singulex technologies in the diagnostics market. As part of the financing, Hironori Hozoji, investment officer for JAFCO Life Science Investment, will join the company's Board of Directors.

"With these funds, we are confident we have the resources to develop our immunoassay technology for use in the diagnostics field," said Philippe Goix, PhD, CEO of Singulex. "Already, the assays we have developed and optimized for our pharmaceutical partners have enabled them to see biomarker level differences in blood samples with and without drugs that they had not been able to see before, thus offering new insights for their clinical trials."

Singulex has closed partnerships with multiple large pharmaceutical companies to use Erenna technology and immunoassays to help them better understand the effects of their compounds early in preclinical studies and clinical trials. With its ability to detect and measure minute protein biomarker changes at very low levels, Singulex's technology also has significant potential for clinical applications in personalized medicine across multiple diseases.

Singulex will use the funds from this financing to deploy its product and services in the emerging molecular clinical diagnostic market. Initially, the company will focus on cardiovascular disease risk diagnostics using its assay platform for the biomarker c Troponin I (cTnI), a well-validated marker for cardiac necrosis.

"Singulex's steady progress in publishing strong data from premier medical schools in the country indicated that the Erenna technology can make significant contributions to the diagnostics field, specifically in the cardiov
'/>"/>

SOURCE Singulex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
2. Karolinska Development Closes Fully Subscribed New Share Issue
3. Concentric Medical Closes on $15 Million Financing
4. Intradigm Closes Final Tranche of $21.4 Million Series B Financing
5. Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing
6. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
7. MicroPhage Closes Latest Financing
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
10. Starfish Ventures Closes Australias Largest Venture Capital Fund With $185 Million Tech Fund
11. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2012)... a timely and reliable way to obtain enough raw ... the tissue they need to build. In a new ... viscosity, and other mechanical properties of adult stem cells ... whether they will turn into bone, cartilage, or fat. ... of extracting the needed cells from a larger and ...
(Date:5/21/2012)... Elsevier,s Computers & Graphics announces the upcoming ... which will incorporate the Collage Authoring Environment, a workflow ... of the 2011 Executable Paper Grand Challenge. The call ... Eurographics 2012 on May 13, during the 3DOR Workshop. ... to embed chunks of executable code and data into ...
(Date:5/21/2012)... International scientific and government experts held a ... use of Oxitec,s genetically modified Aedes aegypti ... Panama. The independent forum was co-organised by ... Institute for Health Studies and the University of Panama. ... institutes as well as the Pan American Health Organisation, ...
(Date:5/18/2012)...  Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that ... CEO, will be presenting at the Seventh Annual ... (Logo:  http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ) The title ... Offer Attractive Targets for Active and Passive Immunotherapy." ... at the Intercontinental Hotel in Boston from 10:15-11:30 ...
Breaking Biology Technology:Physical properties predict stem cell outcome 2Physical properties predict stem cell outcome 3Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 2Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 3
... On January 7,2008, Signalife received a deficiency letter ... it advised that Signalife would need to,comply with ... listing under AMEX Rules 1003(a)(iii). This notification was,triggered ... less than,$50 million, which previously exempted Signalife from ...
... New Agent for CLL Patients Approved by the FDA ... Cephalon, Inc. (Nasdaq:,CEPH) today announced that the U.S. Food ... Injection for the,treatment of patients with chronic lymphocytic leukemia ... American Cancer Society,estimates that more than 15,000 new cases ...
... study setup and launch..., WAYLAND, Mass., March ... clinical trials software, announces the,launch of its Trident ... unique parameter driven + custom pluggable design,leaps ahead ... a new era,of needed scalability, productivity, and ease-of-use ...
Other Biology Technology:AMEX Notifies Signalife That It Has Accepted Signalife's Plan of Compliance 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 3Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 4Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 5Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3
(Date:5/21/2012)... University of Singapore,s (NUS) Department of Biological Sciences and ... a compound that is undergoing preclinical trials as a ... and stop them from growing into a tumour. This ... the first time a research group has provided evidence ... , Building on the new findings, the NUS team ...
(Date:5/21/2012)... teams of Australian and US scientists has found there ... Antarctic Bottom Water found off the coast of Antarctica.,Comparing ... Southern Ocean marine science voyage to historical data dating ... much as a 60 per cent reduction in the ... that drives global ocean currents. , In an intensive ...
(Date:5/20/2012)... (HDAC) inhibitor panobinostat is able to target and ... study published in BioMed Central,s open access journal ... University Health Sciences Center have shown that panobinostat ... reduce tumor growth in mice. , Approximately 15% ... be triple negative. These aggressive tumours are missing ...
Breaking Biology News(10 mins):Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2Latest Southern Ocean research shows continuing deep ocean change 2Latest Southern Ocean research shows continuing deep ocean change 3Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2San Diego State Offers Project Management Programs Beginning in January 61681 1San Diego State Offers Project Management Programs Beginning in January 61681 2Hobbits are a new human species according to the statistical analysis of fossils 10800 1Hobbits are a new human species according to the statistical analysis of fossils 10800 2Marrone Bio Innovations Named an IC20 Company 14914 1Marrone Bio Innovations Named an IC20 Company 14914 2
... Institute on Drug Abuse (NIDA), part of the National ... genes that might increase a person’s ability to abstain ... George Uhl at NIDA’s Intramural Research Program and a ... for Nicotine and Smoking Cessation Research at Duke University ...
... MIT have created an ocean model so realistic that the ... in population patterns that precisely mimic their real-world counterparts. , ... the vast diversity of the invisible forests living in our ... half the oxygen we breathe on Earth. And it does ...
... of millipede was recently discovered by a Northern Arizona ... researcher. , J. Judson Wynne, with the Department ... with the U.S. Geological Survey's Southwest Biological Center, and ... of Land Management (BLM), collected specimens leading to the ...
Other Biology News:NIDA study identifies genes that might help some people abstain from smoking 2MIT's ocean model captures diversity of underwater forests 2MIT's ocean model captures diversity of underwater forests 3Discovery of new cave millipedes casts light on Arizona cave ecology 2Discovery of new cave millipedes casts light on Arizona cave ecology 3